Everything below concerns c-Met receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-12-11. Where a claim depends on a specific study, the study is described rather than over-claimed.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | Derived from angiotensin IV and modified for stability. |
| Proposed mechanism | c-Met/HGF pathway activation | Described as an HGF mimetic in experimental systems. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Name usage varies by supplier and publication. |
| Regulatory status | Not approved as a drug | Sold as a research chemical in some markets. |
| Human trial data | Limited or absent | Most evidence comes from preclinical studies. |
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Scalephobicity and antifouling Coatings for gas evolution reaction electrodes for efficient bubble detachment Breast implants Contact lenses (silicone hydrogels, polyacrylamides, polymacon) Water sustainability: Hydrogels have emerged as promising materials platforms for solar-powered water purification, water disinfection, and atmospheric water generator. Disposable diapers where they absorb urine, or in sanitary napkins Dressings for healing of burn or other hard-to-heal wounds. Wound gels are excellent for helping to create or maintain a moist environment. EEG and ECG medical electrodes using hydrogels composed of cross-linked polymers (polyethylene oxide, polyAMPS and polyvinylpyrrolidone) Encapsulation of quantum dots Environmentally sensitive hydrogels (also known as 'smart gels' or 'intelligent gels'). These hydrogels have the ability to sense changes of pH, temperature, or the concentration of metabolite and release their load as result of such a change. Fibers Glue Granules for holding soil moisture in arid areas Air bubble-repellent (superaerophobicity). Can improve the performance and stability of electrodes for water electrolysis. Culturing cells: Hydrogel-coated wells have been used for cell culture. Biosensors: Hydrogels that are responsive to specific molecules, such as glucose or antigens, can be used as biosensors, as well as in DDS. Cell carrier: Injectable hydrogels can be used to carry drugs or cells for applications in tissue regeneration or 3D bioprinting.
Xanthoria parietina grows at an average rate of about 2.6 mm per year, though growth varies with habitat. Moist sub-montane environments support faster growth (6–7 mm/year), while drier coastal regions slow expansion. Growth peaks in cold, wet seasons (autumn/winter) and declines in warm, dry conditions, such as Mediterranean climates. The slow growth of X. parietina influences its longevity and dispersal. Without active water uptake, high evaporative demand limits metabolism, especially in wind-exposed, low-altitude regions, where desiccation slows thallus expansion and reduces propagule success. In contrast, high humidity supports steady radial growth, allowing long-term persistence, biomass accumulation, and continuous ascospore release. Strong winds both hinder and aid X. parietina. While wind exposure dehydrates thalli and slows growth, it also disperses thallus fragments, which serve as vegetative propagules in the absence of specialized structures, supplementing spore-based dispersal. Xanthoria parietina releases and germinates spores year-round, though germination is faster in summer (4–5 days) and slower in winter. Optimal germination occurs at pH 6, but spores tolerate pH 3–7. Germination success and mycobiont development are influenced by multiple environmental factors. Substrate affects success—germination is higher on agar than in water films. In the laboratory, the ascospores of X. parietina germinate best in liquid nutrient media, particularly malt-yeast extract, which provides essential carbohydrates, amino acids, and vitamins.
Tarui disease (GSD-VII) patients do not experience the "second wind" phenomenon; instead are said to be "out-of-wind." However, they can achieve sub-maximal benefit from lipid metabolism of free fatty acids during aerobic activity following a warm-up.
=== Activation of mTORC1 === The lysosomal membrane is the main area in which mTORC1 is activated. However, some activation can occur in the Golgi apparatus and the peroxisome. In mammalian cells, GTPase RagA and RagB are heterodimers with RagC and RagD, respectively. When enough amino acids are present, RagA/B GTPase becomes activated, which leads to the translocation of mTORC1 from the cytoplasm to the lysosome surface, via the Raptor. This process brings mTORC1 in close enough proximity to Rheb for Rheb to either (1) cause a conformational change to mTORC1, leading to and increase in substrate turnover, or (2) induce kinase activity of mTORC1. Rags do not contain membrane-targeting sequences, and as a result, depend on the entire Ragulator-Rag Complex to bind to the lysosome, activating mTORC1. While most amino acids indirectly activate mTORC1 in mammals, Leucine has the ability to directly activate mTORC1 in cells that are depleted of amino acids. Yeast contain LRS (leucyltRNA synthetase), which is a molecule that can interact with Rags, directly activating the molecule.
pcALCL lesions exhibit large malignant T-cells or null cells (i.e. cells lacking many T-cell receptor proteins) with "Hallmark" cell features of anaplasia, pleomorphism, and kidney- and horse shaped-nuclei. These lesions are often limited to the dermis but can extend into the surrounding subcutaneous tissue and/or epidermis. Rarely, the lesions, termed pyrogenic variants, are rich in polymorphonuclear neutrophils. The neoplastic cells strongly express CD30 (100% of cases), CD2 (78%), CD4 (54–90% of cases), cytotoxicity marker proteins, and various other marker proteins that help distinguish it from other ALCL, cutaneous T-cell lymphomas, and cancers. While these cells typically are ALK-negative, they do express ALK-containing fusion proteins in rare cases. The latter cases have a relatively benign course compared to ALK-positive ALCL and are treated as variants of pcALCL rather than ALK-positive ALCL.
Sources: en.wikipedia.org
== Uses == Many early video games made use of a silent protagonist out of utility, which could be due to technology, time, or budget limitations, or as a narrative device. Whether the player is supposed to be the protagonist or is merely assuming control of an established character and whether the game allows the player freedom of choices that would be difficult to believably justify with spoken narrative influence this decision. Some have cited the 1993 game Myst as an example of a first person adventure where the main character is merely an avatar for the player's choices and dialogue would not be needed or helpful. The 2001 game Grand Theft Auto III has no dialogue for its protagonist, Claude, as is common for games of its time, and this allows players of many backgrounds and personalities to identify with the character they control in the game's open world environment. In the Half-Life series, the protagonist is the silent Gordon Freeman, but is distinct from the player. Game writer Marc Laidlaw, who worked on Half-Life and Portal (which also features a silent protagonist) with game developer Valve, stated that he did not recommend keeping protagonists silent due to the difficulties that arise during development, but noted that limiting oneself to a silent protagonist can lead to more creativity.
Technological research in Brazil is largely carried out in public universities and research institutes, with the majority of funding for basic research coming from various government agencies. Brazil's most esteemed technological hubs are the Oswaldo Cruz Institute, the Butantan Institute, the Air Force's Aerospace Technical Center, the Brazilian Agricultural Research Corporation and the National Institute for Space Research. The Brazilian Space Agency has the most developed space program in Latin America, with significant capabilities in launch vehicles, launch sites, and satellite manufacturing. Brazil is the only country in the Southern Hemisphere involved in the International Space Station (ISS). The country also develops submarines and is the world's third largest aircraft producer, primarily through Embraer. The country is also a pioneer in the search for oil in deep water, from where it extracts 73% of its reserves. Uranium is enriched at the Resende Nuclear Fuel Factory, mostly for research purposes (as Brazil obtains 88% of its electricity from hydroelectricity), and the country's first nuclear submarine is expected to launch in 2029. Brazil is one of the three countries in Latin America with an operational Synchrotron Laboratory (a research facility on physics, chemistry, material science and life sciences), and the only Latin American country with a domestic fabrication plant, the CEITEC. According to the Global Information Technology Report 2009–2010 of the World Economic Forum, Brazil is the world's 61st largest developer of information technology.
Adolescents were also 21.5% more likely to be overweight when watching 4+ hours of TV per day, 4.5% more likely to be overweight when using a computer one or more hours per day, and unaffected by potential weight gain from playing video games. A randomized trial showed that reducing TV viewing and computer use can decrease age-adjusted BMI; however reduced calorie intake was thought to be the greatest contributor to the BMI decrease. Childhood inactivity is linked to obesity in the United States with more children being overweight at younger ages. In a 2009 preschool study 89% of a preschooler's day was found to be sedentary while the same study also found that even when outside, 56 percent of activities were still sedentary. One factor believed to contribute to the lack of activity found was little teacher motivation, but when toys, such as balls were made available, the children were more likely to play.
=== Gene therapy === For patients where an appropriate match for a transplant cannot be found, there have been investigations into the use of gene therapy. Appropriate vectors are selected and modified to express wild type ABCD1, which is then transplanted into the patients using a similar procedure as for a bone marrow or stem cell transplant. Gene therapy has only been tried on a small number of patients, mainly in France. These patients were only considered for gene therapy after there was no HLA match for a traditional transplant. In two reported cases, the gene therapy was successful, with a resolution of the demyelination process up to two years after the procedure. Although the gene therapy was successful in resolving the neurological symptoms, plasma VLCFA levels remained elevated. Elivaldogene autotemcel is pending authorization by the European Commission as of May 2021. While this treatment is effective with 90% of patients being free of major functional disabilities after treatment, it costs $3.0 million per treatment and it comes with several adverse effects including mucositis and alopecia. There are also reports of hematologic cancer development in patients receiving this gene therapy, including myelodysplastic syndrome and acute myeloid leukemia.
== O == oligo - oligodeoxyribonucleotide - oligonucleotide - oligosaccharide-transporting ATPase - oncogene - oncovirus - open reading frame - operator - operon - origin of replication - ornithine(lysine) transaminase - osteomimicry
Sources: en.wikipedia.org
Dihexa is a synthetic peptide derived from angiotensin IV and studied for effects on synaptic plasticity. It is often described as a hepatocyte growth factor mimetic. It is not an approved medication.
It is based on angiotensin IV, a naturally occurring peptide fragment, but dihexa itself is chemically modified and synthetic. The modifications aim to improve stability and activity compared with the parent fragment.
Laboratory studies have used cell-based assays and rodent models. These examine receptor signaling, dendritic spine changes, and behavioral tasks. Published human clinical trial data are lacking.
The lyophilized powder is generally stored at -20 °C or lower, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data may vary by formulation and purity.